Sonoma Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sonoma Pharmaceuticals, Inc.
Better medtech industry-government dialog is needed to improve the adoption of innovative medical devices by the French health care system. The current pathway is not obvious or easy, according to local manufacturers.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
France’s medtech industry association, Snitem, says everything is in place to create a globally-leading start-ups sector locally, but all stakeholders must play their part, and companies should be wary of falling into easy traps.
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
- Medical Devices
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Oculus Technologies Of Mexico, S.A. De C.V., Nvn Therapeutics, Oculus Innovative Sciences Netherlands B.V.